CureDuchenne Launches Campaign to Fund Research and Raise Disease Awareness

Reframing the “Ticking Clock” of Duchenne

The A Cure Can’t Wait campaign, created internally by the nonprofit CureDuchenne and distributed with pro bono support from Horizon Media, aims to reach audiences who may be entirely unfamiliar with the condition. The strategy centers on contrasting the universal joy of childhood birthday milestones with the grim prognosis faced by families living with Duchenne muscular dystrophy (DMD).

“Most parents celebrate these milestones. For us, it’s a reminder that the clock is ticking and I will outlive my child.”

A mother, featured in the CureDuchenne PSA

According to reporting by Newsy Today, the campaign utilizes a mix of broadcast, digital, and out-of-home media to make the stakes of the disease impossible to ignore. The nonprofit is tracking engagement through social media conversation, landing page traffic, and new donations to measure its success in attracting advocates who were unaware of the disease prior to the July 8 launch.

Cardiac Research and the NOX4 Pathway

While the awareness campaign seeks to secure the future of DMD research, scientists at the USF Health Morsani College of Medicine are working on immediate therapeutic targets. A study published in Molecular Therapy on July 17, 2026, identified that the experimental drug Setanaxib may help protect heart function in DMD patients by targeting NOX1 and NOX4 enzymes.

Da-Zhi Wang, director of the Center for Regenerative Medicine at the USF Health Heart Institute, noted that while gene replacement therapies have progressed, the disease remains devastating. The research team found that Setanaxib reduced inflammation and fibrosis in preclinical models, potentially slowing the progression of cardiomyopathy—a serious form of heart disease associated with DMD.

“The NOX4 inhibitor has already been tested in clinical trials for the treatment of lung fibrosis and kidney and liver disease. We hope it will also be tested soon in clinical trials involving patients with DMD to slow the progression of heart disease.”

John Mably, associate professor at USF Health

Investment and Infrastructure Milestones

CureDuchenne reports that it has invested $28 million into scientific innovation over the past two decades. This funding has supported companies responsible for six of the eight FDA-approved therapies currently available, including treatments from Sarepta Therapeutics, Catalyst Pharmaceuticals, and PTC Therapeutics.

Simultaneously, the Jett Foundation has announced a capital campaign for “Jett’s Place,” a 10-acre wellness and retreat center in Norwell, Massachusetts. According to the Jett Foundation’s announcement, the facility is designed to be a barrier-free sanctuary for families affected by DMD.

Clinical Advancements and Future Outlook

The landscape for patients continues to evolve as new therapies reach the clinic. On July 17, 2026, care.choc.org reported that an 8-year-old boy became the first in his region to receive a new FDA-approved gene therapy for DMD. While individual results vary, some patients have already shown improvements in motor skills and function.

With the A Cure Can’t Wait campaign scheduled to run through the end of the year, the focus remains on bridging the gap between current medical management and a long-term cure. As noted by CureDuchenne, the most critical metric for success is whether the campaign can sustain advocacy and funding in what the organization describes as a pivotal moment for Duchenne research.